Literature DB >> 17339159

Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants.

Chien-Hung Chen1, Pei-Ming Yang, Guan-Tarn Huang, Hsuan-Shu Lee, Juei-Low Sung, Jin-Chuan Sheu.   

Abstract

BACKGROUND/
PURPOSE: Taiwan is a hyperendemic area of liver diseases. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two major etiologies of liver diseases in Taiwan. This study investigated the seroprevalence of HBV and HCV in Taiwan.
METHODS: Since 1996, a series of outreach community-based screening programs for liver diseases have been available to the general population aged > or = 18 years. Blood samples were obtained from the subjects and sent for hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV) tests.
RESULTS: The prevalence of HBsAg(+) was 17.3% (27,210/157,720), while the prevalence of anti-HCV(+) was 4.4% (6904/157,720). Geographic variation in HBV and HCV seroprevalence was found, with the highest anti-HCV positive rate in Miaoli County, Chiayi County, Chiayi City, and Yunlin County, and the highest HBsAg positive rate in Keelung City and Yilan City. The HBsAg positive rate progressively decreased after the age of 50 years, while the anti-HCV positive rate progressively increased after the age of 20 years. The estimated total number of HBsAg carriers in the general population > 20 years old is 3,067,307, while the estimated number of anti-HCV positive patients is 423,283.
CONCLUSION: This study estimated a 17.3% seroprevalence of HBV and a 4.4% seroprevalence of HCV in Taiwan. Significant geographic variations in the seroprevalence of HBV and HCV were found. These data suggest the importance of modifying programs for the prevention and treatment of chronic viral hepatitis in Taiwan to reflect its varying prevalence and epidemiology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339159     DOI: 10.1016/S0929-6646(09)60231-X

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  82 in total

1.  Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.

Authors:  Jeng-Fu Yang; Yi-Hui Kao; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wan-Long Chuang; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2010-08-09       Impact factor: 6.047

2.  Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas.

Authors:  Wei-Wen Su; Chien-Hung Chen; Hans Hsienhong Lin; Sheng-Shun Yang; Ting-Tsung Chang; Ken-Sheng Cheng; Jaw-Ching Wu; Shun-Sheng Wu; Chuan-Mo Lee; Chi-Sin Changchien; Chien-Jen Chen; Jin-Chuan Sheu; Ding-Shinn Chen; Sheng-Nan Lu
Journal:  Hepatol Int       Date:  2009-08-07       Impact factor: 6.047

3.  Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome.

Authors:  Ming-Han Chen; Liang-Tsai Hsiao; Ming-Huang Chen; Chang-Youh Tsai; Yi-Hsiang Huang; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2011-08-02       Impact factor: 2.980

Review 4.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

5.  Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.

Authors:  Ming-Jeng Kuo; Hsiu-Hsi Chen; Chi-Ling Chen; Jean Ching-Yuan Fann; Sam Li-Sheng Chen; Sherry Yueh-Hsia Chiu; Yu-Min Lin; Chao-Sheng Liao; Hung-Chuen Chang; Yueh-Shih Lin; Amy Ming-Fang Yen
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 6.  Aging and liver disease.

Authors:  In Hee Kim; Tatiana Kisseleva; David A Brenner
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

7.  Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma.

Authors:  Kiong-Ming Wong; Ming-Lun Yeh; Shih-Chung Chuang; Liang-Yen Wang; Zu-Yau Lin; Shinn-Cherng Chen; Jung-Fa Tsai; Shen-Nien Wang; Kung-Kai Kuo; Chia-Yen Dai; Ming-Lung Yu; King-The Lee; Wan-Long Chuang
Journal:  Indian J Gastroenterol       Date:  2012-08-30

8.  Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma.

Authors:  Ming-Chu Chang; Chien-Hung Chen; Ja-Der Liang; Yu-Wen Tien; Chiun Hsu; Jau-Min Wong; Yu-Ting Chang
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community.

Authors:  Kuo-Chin Chang; Pei-Shan Tsai; Mei-Chin Hsu; Shu-Fen Hung; Chin-Chen Tsai; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2010-01-07       Impact factor: 7.527

Review 10.  Autoimmunity and infection in Sjögren's syndrome.

Authors:  Ann Igoe; R Hal Scofield
Journal:  Curr Opin Rheumatol       Date:  2013-07       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.